Pediatric Infectious Disease

Register      Login

VOLUME 3 , ISSUE 1 ( January-March, 2021 ) > List of Articles


Multiple Giant Coronary Aneurysms in an Infant with Prolonged Fever

Subhajit Dey Sarkar, Priyankar Pal, Prabhas P Giri, Debadatta Mukhopadhyay

Citation Information : Sarkar SD, Pal P, Giri PP, Mukhopadhyay D. Multiple Giant Coronary Aneurysms in an Infant with Prolonged Fever. Pediatr Inf Dis 2021; 3 (1):43-45.

DOI: 10.5005/jp-journals-10081-1268

License: CC BY-NC 4.0

Published Online: 01-03-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Kawasaki disease is a systemic vasculitis, sometimes presenting atypically in infancy, often leading to a late diagnosis, and resulting in devastating consequences. We report a 2-month-old baby presenting with fever of unknown origin. Echo showed giant aneurysms in all three coronary arteries with intraluminal thrombus in one artery that required thrombolysis and anticoagulation.

PDF Share
  1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967;16(3):178–222.
  2. Chen JJ, Ma XJ, Liu F, et al. Epidemiologic features of Kawasaki disease in shanghai from 2008 through 2012. Pediatr Infect Dis J 2016;35(1):7–12.
  3. Wu MH, Chen HC, Yeh SJ, et al. Prevalence and the long-term coronary risks of patients with Kawasaki disease in a general population <40 years: a national database study. Circ Cardiovasc Qual Outcomes 2012;5(4):566–570. DOI: 10.1161/CIRCOUTCOMES.112.965194.
  4. McCrindle BW, Rowley AH, Newburger JW, et al. American heart association rheumatic fever, endocarditis, and Kawasaki disease committee of the council on cardiovascular disease in the young; Council on cardiovascular and stroke nursing; council on ardiovascular surgery and anesthesia; and council on epidemiology and prevention. Circulation 2017;135(17):e927–e999. DOI: 10.1161/CIR.0000000000000484.
  5. Singh S, Agarwal S, Bhattad S, et al. Kawasaki disease in infants below 6 months: a clinical conundrum? Int J Rheum Dis 2016;19(9):924–928. DOI: 10.1111/1756-185X.12854.
  6. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113(22):2606–2612. DOI: 10.1161/CIRCULATIONAHA.105.592865.
  7. Dionne A, Burns JC, Dahdah N, et al. Treatment intensification in patients with Kawasaki disease and coronary aneurysm at diagnosis. Pediatrics 2019;143(6):e2018334.
  8. Friedman KG, Gauvreau K, Hamaoka-Okamoto A, et al. Coronary artery aneurysms in Kawasaki disease: risk factors for progressive disease and adverse cardiac events in the US Population. J Am Heart Assoc 2016;5(9):e003289.
  9. Harada M, Akimoto K, Ogawa S, et al. National Japanese survey of thrombolytic therapy selection for coronary aneurysm: intracoronary thrombolysis or intravenous coronary thrombolysis in patients with Kawasaki disease. Pediatr Int 2013;55(6):690–695. DOI: 10.1111/ped.12187.
  10. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21 year follow-up study of 594 patients. Circulation 1996;94(6):1379–1385. DOI: 10.1161/01.CIR.94.6.1379.
  11. Furuyama H, Odagawa Y, Katoh C, et al. Altered myocardial flow reserve and endothelial function late after Kawasaki disease. J Pediatr 2003;142(2):149–154. DOI: 10.1067/mpd.2003.46.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.